Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis

Pepose, Jay S.; Ahuja, Arjun; Liu, Wenlei; Narvekar, Abhijit; Haque, Reza

doi:10.1016/j.ajo.2019.02.039

Cited by 17 publications

(28 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More recently, Pepose et al. () have shown that PVP‐I 0.6%/dexamethasone 0.1% appeared safe and well tolerated and significantly improved clinical resolution and adenoviral eradication in patients with acute adenoviral conjunctivitis. Furthermore, Musumeci et al.…”

Section: Introductionmentioning

confidence: 99%

In vitro antimicrobial activity of a new ophthalmic solution containing povidone‐iodine 0.6% (IODIM^®)

Pinna

Donadu

Usai

et al. 2019

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose To assess the in vitro antimicrobial activity of a new commercial ophthalmic solution containing povidone‐iodine 0.6% (IODIM®). Methods Staphylococcus aureus ATCC 43300, Pseudomonas aeruginosa ATCC 27853, three ocular bacterial isolates (1 S. epidermidis, 1 S. aureus, 1 P. aeruginosa) and five Candida species were used. The bacterial and fungal isolates were cultured on Columbia blood agar base plates and Sabouraud‐dextrose agar plates, respectively and incubated overnight at 37°C. Bacterial and fungal suspensions in sterile saline solution were prepared to an optical density equal to 0.5 McFarland standard (approximately 108 CFU/ml). Suspensions of the isolates were made in IODIM® solution to obtain a final concentration of 106 CFU/ml. The suspensions were then distributed in conical tubes in a final volume of 1 ml and incubated at 37°C. At different time‐points (1, 5, 10, 15, 20, 25, 30 min and 24 hr), 10 μl of each suspension was removed, seeded on Columbia blood agar base and Sabouraud‐dextrose agar plates and then incubated for 24 hr at 37°C. Positive and negative controls were included in all experiments. Results After 5‐min incubation, there was no bacterial growth on any plate. Conversely, IODIM® failed to kill the Candida isolates after 30 min’ exposure and needed 24 hr to eradicate the organisms. Conclusion IODIM® ophthalmic solution showed in vitro antimicrobial activity against S. epidermidis, S. aureus, P. aeruginosa and Candida species. Results suggest that it may be a potential candidate for the treatment of ocular surface infections and antimicrobial prophylaxis before intravitreal injections.

show abstract

Section: Introductionmentioning

confidence: 99%

In vitro antimicrobial activity of a new ophthalmic solution containing povidone‐iodine 0.6% (IODIM^®)

Pinna

Donadu

Usai

et al. 2019

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…There was no significant difference between the effect of topical 1.25% PVP-I and the aforementioned antibiotics [17]. Another recent paper has also shown clinical resolution and adenoviral eradication in patients with acute adenoviral conjunctivitis treated with a combination of Dexamethasone and PVP-I 0.6% [18].…”

Section: Discussionmentioning

confidence: 88%

Corneal Ulcer Treated with 0.66% Nanoemulsion Povidone-Iodine: A Case Report

Bordin

2020

Am J Case Rep

View full text Add to dashboard Cite

Unusual clinical course Background: Corneal ulceration is caused by various corneal diseases, including infection, inflammatory disease, neurotrophic keratitis, dry-eye, autoimmune disease, and blepharitis. Treatment should be based on the etiology. In cases of infection, corneal scraping and pathogen culture should be carried out before treatment. Bacterial pathogens are the most common etiology, but it can be caused also by viruses, fungi, and protozoa. Quinolones are the first-line drug for bacterial keratitis, but the treatment should be changed according to the culture and drug sensitivity test results. The purpose of this case report is to show the resolution of a corneal ulcer case unusually treated with 0.66% povidone-iodine (PVP-I). Case Report: A 61-year-old man showed signs of pain, redness, watering, and photophobia in the left eye (oculus sinister; OS) over a 5-month period, starting as conjunctivitis and degenerating into keratitis. Clinical examination revealed an ulcer in the inferior cornea and biomicroscopy analysis confirmed this diagnosis. Previous therapies, starting with antibiotics first and then antiviral medications, were unable to control the signs and symptoms. Therefore, treatment with 0.66% PVP-I, based on its antiseptic activity, was administered 3 times a day for 4 weeks. Conclusions: PVP-I 0.66%, an antiseptic with broad-spectrum activity against bacteria, fungi, viruses, and protozoa, was found to be effective in treating the signs and symptoms of the ulcer until its complete closure and resolution. It could be a useful therapeutic tool when the pathogen is unknown, as in this case. Its use for treatment of corneal ulcers warrants further investigation.

show abstract

“…Recently, Kovalyuk et al described that in patients affected with adenoviral keratoconjunctivitis the fastest improvement in red eyes, discharge, superficial punctate keratitis and pseudomembranes was in the group treated with povidone-iodine 1.0% and dexamethasone 0.1% eyedrops, compared to those treated with dexamethasone 0.1% or hypromellose 0.3% [29]. Moreover, some authors used Povidone-Iodine 0.6% and Dexamethasone 0.1% ophthalmic suspension in patients with acute adenoviral conjunctivitis reporting that its use was safe and well tolerated, significantly improving adenoviral eradication and clinical resolution [30]. The safety of this treatment in patients with clinically suspected acute viral conjunctivitis was recently confirmed by other authors who, however, failed to demonstrate its therapeutic superiority [31].…”

Section: Discussionmentioning

confidence: 99%

The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial

et al. 2020

View full text Add to dashboard Cite

Purpose To determine whether topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops reduces clinical signs and infectious viral titers of presumed viral conjunctivitis more than tobramycin/dexamethasone eye drops alone. Methods Prospective, single-blind, randomized, parallel-groups trial. Eighty patients with a clinical diagnosis of presumed viral conjunctivitis were randomizedly divided into two treatment groups: a study group and a control group, 40 for each group. Patients in the study group received topical tobramycin 0.3%/ dexamethasone 0.1% eye drops, plus ozonized oil eye drops, both four times daily; patients in the control group received only topical tobramycin 0.3%/dexamethasone eye drops four times daily. The treatment was for seven days in both groups. Swabs were taken from the conjunctival fornix for adenovirus PCR analysis on the day of recruitment and at seven days

show abstract

Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis

Cited by 17 publications

References 12 publications

In vitro antimicrobial activity of a new ophthalmic solution containing povidone‐iodine 0.6% (IODIM^®)

In vitro antimicrobial activity of a new ophthalmic solution containing povidone‐iodine 0.6% (IODIM^®)

Corneal Ulcer Treated with 0.66% Nanoemulsion Povidone-Iodine: A Case Report

The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial

Contact Info

Product

Resources

About

Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis

Cited by 17 publications

References 12 publications

In vitro antimicrobial activity of a new ophthalmic solution containing povidone‐iodine 0.6% (IODIM®)

In vitro antimicrobial activity of a new ophthalmic solution containing povidone‐iodine 0.6% (IODIM®)

Corneal Ulcer Treated with 0.66% Nanoemulsion Povidone-Iodine: A Case Report

The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial

Contact Info

Product

Resources

About

In vitro antimicrobial activity of a new ophthalmic solution containing povidone‐iodine 0.6% (IODIM^®)

In vitro antimicrobial activity of a new ophthalmic solution containing povidone‐iodine 0.6% (IODIM^®)